BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18770864)

  • 1. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.
    Martini M; Pallini R; Luongo G; Cenci T; Lucantoni C; Larocca LM
    Int J Cancer; 2008 Dec; 123(12):2955-60. PubMed ID: 18770864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
    Zhou H; Miki R; Eeva M; Fike FM; Seligson D; Yang L; Yoshimura A; Teitell MA; Jamieson CA; Cacalano NA
    Clin Cancer Res; 2007 Apr; 13(8):2344-53. PubMed ID: 17438093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
    Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
    Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
    Pierconti F; Martini M; Pinto F; Cenci T; Capodimonti S; Calarco A; Bassi PF; Larocca LM
    Prostate; 2011 Feb; 71(3):318-25. PubMed ID: 20717995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells.
    Kim MH; Kim MS; Kim W; Kang MA; Cacalano NA; Kang SB; Shin YJ; Jeong JH
    PLoS One; 2015; 10(4):e0123133. PubMed ID: 25849377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients.
    Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R
    Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.
    Feng Y; Wang Z; Bao Z; Yan W; You G; Wang Y; Hu H; Zhang W; Zhang Q; Jiang T
    PLoS One; 2014; 9(3):e91829. PubMed ID: 24633048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma.
    Dai L; Han Y; Yang Z; Zeng Y; Liang W; Shi Z; Tao Y; Liang X; Liu W; Zhou S; Xing Z; Hu W; Wang X
    J Cell Mol Med; 2023 Aug; 27(15):2194-2214. PubMed ID: 37315184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
    Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
    PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR.
    Pulverer W; Hofner M; Preusser M; Dirnberger E; Hainfellner JA; Weinhaeusel A
    Clin Neuropathol; 2014; 33(1):50-60. PubMed ID: 23993306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma multiforme clinical outcomes.
    Saraiva-Esperón U; Ruibal A; Herranz M
    J Neurol Sci; 2014 Dec; 347(1-2):325-31. PubMed ID: 25467143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
    Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
    Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.